Top

Published in:

Open Access 01-12-2018 | Research

MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases

Authors: Shirong Ma, Linni Fan, Yixiong Liu, Yingmei Wang, Kangjie Yu, Lifeng Wang, Na Fang, Fang Liu, Shuangping Guo, Zhe Wang

Published in: Diagnostic Pathology | Issue 1/2018

Abstract

Background

Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas. Previous studies have shown that MET protein overexpressed in MFS patients and can serve as a prognostic factor. The reasons for MET protein overexpression include amplification of the MET gene, which is located on chromosome 7q. Triggered by an index case harboring chromosome 7 polysomy rather than MET gene amplification in myxofibrosarcoma, we investigated chromosome 7 polysomy in more cases.

Methods

Immunohistochemistry and fluorescence in situ hybridization (FISH) were performed in 30 MFS cases (including 2 epithelioid variant) to detect the expression of MET protein and gene status.

Results

MET was overexpressed in 14 cases out of 30, while thirteen cases were in higher FNCLCC grades (Grade 2–3). FISH showed that 11 cases having 3 signals on average of Met and more than 3 signals (Mean: 4.6) of centromere 7q (CEP7q). The MET/CEP7 ratio was about 0.65 on average, suggesting that chromosome 7 polysomy, rather than Met gene amplification, leading to the overexpression of MET protein in MFS. MET overexpression and chromosome 7 polysomy are positively correlated with higher Ki-67 index and higher grade and might have a high risk of local recurrence and metastasis.

Conclusions

It might reveals another explain of MET overexpression in myxofibrosarcoma, providing a clue for the therapy of MFS.

Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20(1):80–6.CrossRefPubMed

Nascimento AF, Bertoni F, Fletcher CD. Epithelioid variant of myxofibrosarcoma: expanding the clinicomorphologic spectrum of myxofibrosarcoma in a series of 17 cases. Am J Surg Pathol. 2007;31(1):99–105.CrossRefPubMed

Yang Y, Wu N, Shen J, Teixido C, Sun X, Lin Z, et al. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. Gastric Cancer. 2015;

Paliga A, Marginean H, Tessier-Cloutier B, Purgina B, Jonker D, Marginean EC. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas. American journal of clinical oncology. 2015;

Refaat T, Donnelly ED, Sachdev S, Parimi V, El Achy S, Dalal P, et al. C-met overexpression in cervical Cancer, a prognostic factor and a potential molecular therapeutic target. Am J Clin Oncol. 2015;

Abou-Bakr AA, Elbasmi A. C-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. The Gulf journal of oncology. 2013;1(14):28–34.PubMed

Chen Y, Takita J, Mizuguchi M, Tanaka K, Ida K, Koh K, et al. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes, chromosomes & cancer. 2007;46(4):348–58.CrossRef

Patane S, Avnet S, Coltella N, Costa B, Sponza S, Olivero M, et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res. 2006;66(9):4750–7.CrossRefPubMed

Grabellus F, Konik MJ, Worm K, Sheu SY, van de Nes JA, Bauer S, et al. MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions. Tumour Biol. 2010;31(3):157–63.CrossRefPubMed

10.

Lee JC, Li CF, Fang FM, Wang JW, Jeng YM, Yu SC, et al. Prognostic implication of MET overexpression in myxofibrosarcomas: an integrative array comparative genomic hybridization, real-time quantitative PCR, immunoblotting, and immunohistochemical analysis. Mod Pathol. 2010;23(10):1379–92.CrossRefPubMed

11.

Li Y, Li W, He Q, Xu Y, Ren X, Tang X, et al. Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 2015;6(15):13309–19.PubMedPubMedCentral

12.

Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol. 2012;27(2):197–207.PubMed

13.

Seo AN, Park KU, Choe G, Kim WH, Kim DW, Kang SB, et al. Clinical and prognostic value of MET gene copy number gain and chromosome 7 polysomy in primary colorectal cancer patients. Tumour biol. 2015;

14.

Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH Jr, Blumenschein GR Jr, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31(32):4105–14.CrossRefPubMedPubMedCentral

15.

Fletcher CD. BJAHPCea: WHO classification of tumors of soft tissue and bone. Lyon: IARC Press; 2013.

16.

Castronovo C, Arrese JE, Quatresooz P, Nikkels AF. Myxofibrosarcoma: a diagnostic pitfall. Rare tumors. 2013;5(2):60–1.CrossRefPubMedPubMedCentral

17.

Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118(2):518–27.CrossRefPubMed

18.

Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18(3):720–5.CrossRefPubMed

19.

Kikuta K, Kubota D, Yoshida A, Suzuki Y, Morioka H, Toyama Y, et al. An analysis of factors related to recurrence of myxofibrosarcoma. Jpn J Clin Oncol. 2013;43(11):1093–104.CrossRefPubMed

20.

Riouallon G, Larousserie F, Pluot E, Anract P. Superficial myxofibrosarcoma: assessment of recurrence risk according to the surgical margin following resection. A series of 21 patients. Orthop Traumatol Surg Res. 2013;99(4):473–7.CrossRefPubMed

21.

Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82(1):361–7.CrossRefPubMed

22.

Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006;19(3):407–16.CrossRefPubMed

23.

Willems SM, Mohseny AB, Balog C, Sewrajsing R, Briaire-de Bruijn IH, Knijnenburg J, et al. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med. 2009;13(7):1291–301.CrossRefPubMedPubMedCentral

24.

Glukhova L, Lavialle C, Fauvet D, Chudoba I, Danglot G, Angevin E, et al. Mapping of the 7q31 subregion common to the small chromosome 7 derivatives from two sporadic papillary renal cell carcinomas: increased copy number and overexpression of the MET proto-oncogene. Oncogene. 2000;19(6):754–61.CrossRefPubMed

25.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol. 2011;24(8):1146–55.CrossRefPubMed

26.

Buckingham LE, Coon JS, Morrison LE, Jacobson KK, Jewell SS, Kaiser KA, et al. The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib. J Thorac Oncol. 2007;2(5):414–22.CrossRefPubMed

27.

Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013;26(12):1632–41.CrossRefPubMed

28.

Weidner KM, Sachs M, Birchmeier W. The met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol. 1993;121(1):145–54.CrossRefPubMed

Title: MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases
Authors: Shirong Ma
Linni Fan
Yixiong Liu
Yingmei Wang
Kangjie Yu
Lifeng Wang
Na Fang
Fang Liu
Shuangping Guo
Zhe Wang
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Diagnostic Pathology / Issue 1/2018
Electronic ISSN: 1746-1596
DOI: https://doi.org/10.1186/s13000-018-0733-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

MET-overexpressing myxofibrosarcoma frequently exhibit polysomy of chromosome 7 but not MET amplification, especially in high-grade cases: clinical and pathological review of 30 myxofibrosarcoma cases

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Novel t(1;2)(p36.1;q23) and t(7;19)(q32;q13.3) chromosomal translocations in ischemic fasciitis: expanding the spectrum of pseudosarcomatous lesions with clonal pathogenetic link

Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer

HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis

Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

Genetic and molecular origins of colorectal Cancer among the Iranians: an update

Bacterial outer membrane vesicles, a potential vaccine candidate in interactions with host cells based